论文部分内容阅读
目的 :观察蜂毒素缓释制剂瘤内注射的减毒增效作用。 方法 :以低、中、高 3种剂量 (0 .16、0 .32和 1.6 m g/ kg)的蜂毒素 -泊洛沙姆 40 7缓释剂对 H2 2 荷瘤小鼠施瘤内注射后 ,以小鼠生存期、血细胞、肝功能及其肿瘤病理形态变化为指标观察其体内抗肿瘤作用。 结果 :(1)蜂毒素缓释制剂的毒性明显低于单纯蜂毒素 (P<0 .0 5 ) ;(2 )蜂毒素缓释剂型治疗组肿瘤生长受到显著抑制 ,低、中、高剂量的抑瘤率分别为 2 0 .7%、36 .5 %、5 3.3% ;肿瘤组织广泛坏死 ,治疗后平均生存期明显延长 (P<0 .0 5 ) ,综合疗效优于单纯蜂毒素组。 结论 :蜂毒素缓释制剂瘤内局部注射能够通过延缓蜂毒素的释放速度 ,增加其与肿瘤细胞直接作用的时间等途径达到减毒增效的目的。
Objective: To observe the attenuated and synergistic effects of intratumoral injection of melittin sustained-release preparations. METHODS: After low-, medium-, and high-dose (0.16, 0.32, and 1.6 mg/kg) melittin poloxamer 40 7 sustained release agents were administered intratumorally to H22 tumor-bearing mice. , To observe the anti-tumor effect in vivo by using mouse survival time, blood cells, liver function and pathological changes of tumor as indicators. RESULTS: (1) The toxicity of melittin sustained-release preparation was significantly lower than that of melittin alone (P<0.05); (2) The tumor growth was significantly inhibited in the melittin sustained-release treatment group, with low, medium, and high doses. The tumor inhibition rates were 20.7%, 36.5%, and 53.3% respectively. The tumor tissues were extensively necrotic and the average survival time was significantly prolonged after treatment (P<0.05). The overall curative effect was better than that of the simple melittin group. Conclusion: The intratumoral injection of melittin sustained-release preparation can achieve the purpose of attenuating and increasing efficacy by delaying the release rate of melittin and increasing the time of direct action with tumor cells.